We've created this area for all COVID-19 information relevant to clinical trials we have gathered.
In line with the national guidance and emphasis on the safety and well-being of patients, research participants and their families, and health care professionals, researchers and other staff involved in patient care and research, ACTA strongly supports the continuation of investigator-led trials, where it is safe to do so, and with due consideration to any protocol amendments appropriate for the current COVID-19 pandemic.
Subscribe to the ACTA newsletter if you would like to receive updates to guidance and other key information about clinical trials and COVID-19.
Key COVID-19 Resources for Clinical Trials
-
National Medical Stockpile: Supply of experimental medicines to support clinical trials
As part of the Commonwealth Government’s response to COVID-19, the National Medical Stockpile (NMS) will secure supply of a number of experimental medicines for use in clinical trials, when those medicines cannot be obtained through usual supply chains.
-
COVID-19: Guidance on Australian clinical trials for institutions, HRECs, researchers and sponsors
A joint statement has been released reflecting the shared views of state and territory Departments of Health, the Therapeutic Goods Administration (TGA), National Health and…
-
Australian Commission on Safety and Quality in Health Care Health Service Accreditation (AHSSQA) during the COVID-19 pandemic
Due to the COVID-19 pandemic, changes to the accreditation requirements to the National Safety and Quality Health Service (NSQHS) Standards are being enacted. The Australian…
-
National COVID-19 Clinical Evidence Taskforce: New Clinical Guidelines for COVID-19 to help Australian clinicians deliver best care
A coalition of peak Australian experts have come together to develop new ‘living guidelines’ that will provide continuously-updated, evidence-based guidance to clinicians treating people with confirmed or…
Latest Resources
Latest News
-
Vaccines alone won’t keep Australia COVID-safe, review finds
-
Symposium: Social and ethical implications of the COVID-19 pandemic
-
Media Release: Australian Clinical Trials Alliance commends the Health Minister’s vision to expedite clinical trials in Australia
-
MRFF Grant Opportunity
-
Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency: Guidance for Industry
-
ACTA STInG: signatories to open letters addressing statistical analysis and data integrity in COVID-19 publications
-
Australian Clinical Trials Alliance celebrating and honouring clinical trials on International Clinical Trials Day
-
FIND AND SHARE CLINICAL TRIAL SOLUTIONS AT BEYOND COVID-19: A SOLUTION-FOCUSSED FORUM
-
NSW Health COVID-19 Research Grants
-
National Medical Stockpile: Supply of experimental medicines to support clinical trials
-
Tweetchats with PRAXIS and ACTA
-
CTTI recommendations for best practice in clinical trials during COVID-19 pandemic
-
FDA releases final update on managing clinical trials during COVID-19
-
ACTA statement on COVID-19
-
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
-
COVID-19 and clinical trial updates
-
State and Territory Clinical Trials Contacts
-
COVID-19: Queensland Health Operational Guidance for sponsors, trial sites, ethics committees, research governance officer/s and researchers
-
The Lancet COVID-19 Resource Centre
-
COVID-19 Expert Database
-
National COVID-19 Clinical Evidence Taskforce: New Clinical Guidelines for COVID-19 to help Australian clinicians deliver best care
-
JAMA recommendations on maintaining clinical trial integrity during COVID-19 pandemic
-
The UK’s EPPI-Centre has released a list of COVID-19 resources
-
PRAXIS Managing Clinical Trials webinar recording now available
-
The US Food and Drug Administration (FDA) guidance on conduct of clinical trials of medical products during COVID-19 pandemic was updated 27 March 2020
-
Victorian Coordinating Office for Clinical Trial Research update
-
Survey: Cochrane COVID-19 Core Outcome Set Project
-
Australian Commission on Safety and Quality in Health Care Health Service Accreditation (AHSSQA) during the COVID-19 pandemic
-
Medical Research Future Fund COVID 19 funding
-
ClinTrial Refer COVID-19 app access
-
NHMRC extensions due to COVID-19 impact on researchers
-
Australian Research Council extensions due to COVID-19 impact on researchers
-
Australian Commission on Safety and Quality in Health Care extends timeline for National Clinical Trials Governance Pilot due to COVID-19 pandemic
-
New South Wales Office for Health and Medical Research COVID-19 Guidance
-
HealthMatch Clinical Trials Tracker – See clinical trials in action during the COVID-19 pandemic
-
NHMRC seeks experts to assess COVID-19 grant applications
Latest Events
-
Trial Participants & COVID-19: considerations and strategies for running trials during the pandemic
-
Clinical Trials for COVID-19 Treatment and Prevention
-
Pharmacovigilance and Regulatory Affairs & COVID-19: considerations and strategies for running trials during the pandemic
-
Private Sector & COVID-19: considerations and strategies for running trials during the pandemic
-
Academics & COVID-19: considerations and strategies for running trials during the pandemic
-
Role of Clinical Trial Sponsors & COVID-19: considerations and strategies for running trials during the pandemic
-
Tweetchats with PRAXIS and ACTA
-
Best Practice Guidance for Clinical Trial Sites in COVID-19: Consolidating the information
-
Ethics Committees and Governance & COVID-19: considerations and strategies for running trials during the pandemic
-
Jurisdictions: Federal/States & COVID-19: considerations and strategies for running trials during the pandemic
-
Peak Bodies and TGA & COVID-19: considerations and strategies for running trials during the pandemic